727993-67-1

Upstream product

• 102-50-1 2-methyl-4-methoxyaniline 
• 4341-76-8 Ethyl 2-butynoate 
• 1235407-66-5 1-(4-methoxy-2-methylphenyl)pyrrolidin-2-imine hydrobromide 
• 1092380-15-8 4-chloro-N-[2-methyl-4-(methyloxy)phenyl]butanamide 
• 727993-66-0 1-[2-methyl-4-(methyloxy)phenyl]-2-pyrrolidinone 
• 626-34-6 ethyl aminocrotonate 

Downstream Products

• 727993-70-6 4-iodo-6-methyl-1-[2-methyl-4-(methyloxy)phenyl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridine 
• 786701-13-1 Emicerfont 
• 727993-69-3 6-methyl-1-[2-methyl-4-(methyloxy)phenyl]-1,2,3,7-tetrahydro-4H-pyrrolo[2,3-b]pyridin-4-yl trifluoromethanesulfonate 

Relevant academic research and scientific papers

Identification of a manufacturing route of novel CRF-1 antagonists containing a 2,3-Dihydro-1 H-pyrrolo[2,3-b]pyridine moiety

A case study on the synthesis of novel CRF-1 antagonists containing the 2,3-dihydro-1H-pyrrolo[2,3-b]pyridine moiety is presented. The development of ever more efficient synthetic routes allowed the progression of three candidates at the same time. A manu

HETEROARYL- SUBSTITUTED PYRROLO` 2, 3- B! PYRIDINE DERIVATIVES AS CRF RECEPTOR ANTAGONISTS

The present invention provides compounds of formula (I) including stereoisomers, prodrugs and pharmaceutically acceptable salts or solvates thereof, to processes for their preparation, to pharmaceutical compositions containing them and to their use in the treatment of conditions mediated by corticotropin-releasing factor (CRF).